Adeona, Intrexon ink deal for DNA-based therapy in PAH treatment
Adeona Pharmaceuticals has formed a global exclusive channel collaboration with Human Therapeutics Division of Intrexon to develop and commercialize a DNA-based therapeutic for treating pulmonary arterial hypertension (PAH).
The development of therapeutic will make use of Intrexon's UltraVector platform and RheoSwitch Therapeutic System.
Adeona will utilize Intrexon's transgene engineering platform for the controlled, precise and continuous in vivo cellular production of prostaglandin synthase (PGIS), a specific effector enzyme that regulates the production of prostacyclin.
Prostacyclin is a short-acting vasodilator and inhibitor of platelet aggregation that has demonstrated a survival benefit in primary pulmonary hypertension patients.
As per the agreement, Intrexon will take up the charge of certain aspects of manufacturing and technology discovery efforts.
Adeona will be responsible for conducting preclinical and clinical development of candidates, as well as for other aspects of manufacturing and the commercialization of the candidate product.
Related Insight
Suppliers Directory
Vaisala - Measurement Instruments and Continuous Monitoring System for Critical Environments in Life Science and High-Technology
Vaisala is a global leader in environmental and industrial measurement.
Production & Manufacturing > Process & Production > Suppliers
Grundfos - Pumps and Pump Solutions
Grundfos is a Danish-based pump manufacturer engaged in the development, manufacturing and marketing of pumps, motors, monitors and controls for a broad range of business areas.
Production & Manufacturing > Process & Production > Suppliers
Tecnosoft - Monitoring Systems for Temperature, Humidity and Pressure
Tecnosoft is a system development company working for big third party companies while also steering its own product line with its own brand. We have a lot of experience and a great know-how in the medical and geotechnical industry, having developed and produced data acquisition systems for both markets, in Italy and all around the world, for different leading companies.
Production & Manufacturing > Process & Production > Suppliers
Rotronic - Leading Manufacturer of High Precision Humidity & Temperature Instrumentation
Rotronic is a world leading manufacturer of high precision humidity and temperature instrumentation with more than 40 years' experience in humidity measurement. They are a family owned group of companies with headquarters in Switzerland and more than 40 subsidiaries and distributors worldwide
Production & Manufacturing > Process & Production > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Process & Production Intelligence
Continuous Process Powder Wetting
Published by IKA®
Production & Manufacturing > Process & Production > White Papers
MiniColumns for 96 Array Chromatography
Published by Atoll
Production & Manufacturing > Process & Production > White Papers
GRACO's New FDA Pumps
Published by GRACO PBR
Production & Manufacturing > Process & Production > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.